静脉溶栓作为HeartWare HVAD左心室辅助装置泵血栓一线治疗的单中心经验
该研究回顾性分析了2006年3月至2018年11月单中心30例Medtronic/HeartWare HVAD左心室辅助装置患者的48次泵血栓事件,评估静脉阿替普酶作为一线溶栓治疗的结果。溶栓作为一线治疗用于28例患者的44次事件,溶栓成功率61.4%,联合后续心脏移植或装置更换的成功率为81.8%,但血栓栓塞和出血并发症常见,15.9%的事件中泵血栓致命。结论认为静脉溶栓可作为合理的一线治疗选择,但需个体化权衡风险与获益。
要点
- HVAD泵血栓静脉溶栓一线治疗成功率61.4%,联合后续移植或换泵达81.8%。
- 溶栓相关严重并发症及多器官衰竭导致15.9%的泵血栓事件死亡。
- 颅内出血和动脉血栓栓塞发生率分别为4.5%和11.5%。
核心结论
- 静脉溶栓作为Medtronic/HeartWare HVAD泵血栓的一线治疗是合理选择,且不排除后续心脏移植或装置更换。
- 但血栓栓塞和出血并发症常见,需个体化权衡不同治疗策略的风险与获益。
研究设计与样本
- 单中心回顾性研究,纳入2006年3月至2018年11月30例Medtronic/HeartWare HVAD左心室辅助装置患者的48次泵血栓事件。
- 静脉阿替普酶作为一线溶栓治疗,仅在对溶栓失败或无禁忌时考虑换泵或紧急心脏移植。
主要发现
- 溶栓作为一线治疗用于28例患者的44次泵血栓事件(无溶栓禁忌)。
- 溶栓成功率为61.4%,55.6%的事件需要超过1个周期的溶栓。
- 溶栓联合心脏移植或装置更换的合并成功率为81.8%。
- 15.9%的事件中泵血栓致命,死因为溶栓相关严重并发症(9.1%)或多器官衰竭终止治疗(6.8%)。
- 溶栓后颅内出血和动脉血栓栓塞发生率分别为4.5%和11.5%。
临床怎么用
- 对无溶栓禁忌的HVAD泵血栓患者,可考虑静脉阿替普酶作为一线治疗。
- 溶栓失败或存在禁忌时,应及时评估换泵或紧急心脏移植。
- 溶栓过程中需警惕颅内出血和动脉血栓栓塞等并发症。
- 治疗决策应基于个体化评估,权衡溶栓与装置更换的风险和获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We reviewed our institutional experience with intravenous thrombolysis (TL) as first-line therapy in patients with Medtronic/HeartWare HVAD left ventricular assist device pump thrombosis (PT). METHODS: From March 2006 to November 2018, 30 Medtronic/HeartWare HVAD left ventricular assist device patients had 48 PT events. We analysed outcomes with intravenous Alteplase as a first-line therapy for PT. Pump exchange or urgent heart transplantation was only considered after the failure of TL or existing contraindications to TL. RESULTS: TL was used as the first-line therapy in 44 PT events in 28 patients without a contraindication to TL. TL was successful in 61.4% of PT events. More than 1 cycle of TL was necessary in 55.6% of events. The combined success of TL and heart transplantation or device exchange was 81.8%. In 15.9% of events, PT was fatal. Causes of death were severe complications (9.1%) related to TL or discontinuation of therapy for multi-organ failure (6.8%). Intracranial bleeding and arterial thromboembolism were observed in 4.5% and 11.5% of the PT events after TL. CONCLUSIONS: Intravenous TL as a first-line therapy for PT in Medtronic/HeartWare HVAD patients can be a reasonable treatment option and does not preclude subsequent heart transplantation or device exchange. However, thromboembolic and bleeding complications are common. The decision to perform TL or device exchange should, therefore, be made on an individual basis after balancing the risks and benefits of different treatment approaches.
引用
- Dimitrov K, Maier J, Sandner S, et al. Thrombolysis as first-line therapy for Medtronic/HeartWare HVAD left ventricular assist device thrombosis. Eur J Cardiothorac Surg. 2020. PMID: 32920645. doi:10.1093/ejcts/ezaa180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。